GRI Bio (GRI) Total Non-Current Liabilities (2020 - 2024)
GRI Bio (GRI) posted quarterly Total Non-Current Liabilities of $1.8 million for Q1 2024, down 4.94% year-over-year from $1.9 million in Q2 2023, and down 33.63% quarter-over-quarter from $2.7 million in Q4 2023.
GRI Bio (GRI) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
GRI Bio's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $1.8 million for Q1 2024.
- In Q1 2024, Total Non-Current Liabilities fell 4.94% year-over-year to $1.8 million; the TTM figure through Mar 2024 stood at $1.8 million (down 4.94% YoY), while the FY2023 annual figure was $2.7 million, up 34.16% from the prior year.
- Total Non-Current Liabilities for Q1 2024 stood at $1.8 million, down from $2.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $4.3 million in Q2 2022, with the low at $1.3 million in Q3 2021.
- The 5-year median for Total Non-Current Liabilities is $2.0 million (2022), against an average of $2.2 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities surged 158.65% in 2022, then plunged 64.35% in 2023.
- GRI Bio's Total Non-Current Liabilities stood at $2.2 million in 2020, then rose by 9.2% to $2.4 million in 2021, then slipped by 17.87% to $2.0 million in 2022, then jumped by 34.16% to $2.7 million in 2023, then plunged by 33.63% to $1.8 million in 2024.
- Business Quant data shows GRI's Total Non-Current Liabilities at $1.8 million in Q1 2024, $2.7 million in Q4 2023, and $2.2 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 9.32 Bn |
| 10 | GRI Bio | 3.03 Mn | 3.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | 2.69 Mn |
| Sep 30, 2023 | 2.16 Mn |
| Jun 30, 2023 | 1.54 Mn |
| Mar 31, 2023 | 1.88 Mn |
| Dec 31, 2022 | 2.01 Mn |
| Sep 30, 2022 | 1.89 Mn |
| Jun 30, 2022 | 4.32 Mn |
| Mar 31, 2022 | 2.54 Mn |
| Dec 31, 2021 | 2.45 Mn |
| Sep 30, 2021 | 1.31 Mn |
| Jun 30, 2021 | 1.67 Mn |
| Dec 31, 2020 | 2.24 Mn |